For small-cap biotech investors, a single date on the calendar can matter more than a quarter's wort

NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced th

BlackRock Inc. bought a new stake in shares of Invivyd, Inc. (NASDAQ: IVVD) in the second quarter, a

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced th

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday&#3

Invivyd continues to expect top-line data from the VYD2311 program around the end of Q3 2026. At tha

Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced th

Cantor Fitzgerald analyst Josh Schimmer reiterates Invivyd (NASDAQ:IVVD) with a Overweight and ma

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Es

NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced fin

NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the C

NEW HAVEN, Conn., July 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge”

Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparis

NEW HAVEN, Conn., June 16, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced enr

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy a

Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study tes

Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study tes

LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA

NEW HAVEN, Conn., June 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and e

NEW HAVEN, Conn., June 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the

NEW HAVEN, Conn. , May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after stro

Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript

Invivyd (NASDAQ:IVVD) reported quarterly losses of $(0.13) per share which missed the analyst consen

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody a

U.S. stocks fell, Dow Jones down 100+ points. BlackBerry (NYSE:BB) reported strong Q4 results and sa

Invivyd expands VYD2311 COVID study, delays timeline to Q3 2026, and advances measles antibody VMS06

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accum

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

Invivyd (NASDAQ:IVVD) reported quarterly earnings of $0.02 per share which beat the analyst consensu